Skip to main content

Table 2 Main side effects in the two cohorts of patients

From: High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study

Cohort

Toxicity G3-G4

 

Toxicity G1-G2

 

Neutropenia

Thrombopenia

Anemia

Others

 

Neutropenia

Thrombopenia

Anemia

Others

Cohort A Schedule 1,8,28

1/7 pts

3/7 pts

0/7 pts

0/7

 

4/7

4/7

4/7

4/7 (1 transaminase increasing; 3 nausea-vomiting)

Cohort B Schedule 1, 21

0/7 pts

1/7 pts

0/7 pts

0/7

 

6/7

5/7

5/7

5/7 (1 asthenia; 4 nausea-vomiting)